[Respiratory syncytial virus infection in childhood].
Respiratory syncytial virus is the most frequent cause of respiratory tract infections in infants and is responsible for annual winter epidemics of acute bronchiolitis. Over the last decades medical therapy has remained unchanged and controversial, despite intensive research. Inhaled bronchodilators are often not effective and should be discontinued if no beneficial response can be documented. Steroids and ribavirin are not indicated in previously healthy infants with acute RSV bronchiolitis. There is some evidence, however, that certain risk groups may benefit from their use. With good supportive care the mortality from RSV infection is now low. Postinfectious alterations in lung function are usually transient and reversible. High-risk infants can be protected from severe RSV infections by monthly infusions of RSV immune globulins. This treatment modality has, however, not gained wide acceptance because of the benign nature of the disease and the high costs and side effects of regular immune globulin infusions. An international consensus statement on the treatment of RSV bronchiolitis may help to reduce the wide differences in clinical practice.
Hammer
J
J
Intensivmedizin/Pneumologie, Universitäts-Kinderklinik Basel. hammer@ubaclu.unibas.ch
D001988:Bronchiolitis / Q000175:diagnosis / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007116:Immunization, Passive; D007223:Infant; D011379:Prognosis; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis* / Q000628:therapy; D018113:Respiratory Syncytial Virus, Human; D012140:Respiratory Tract Diseases / Q000175:diagnosis / Q000628:therapy
Die RSV-Infektion im Kindesalter.